• Molecular NameClorazepate
  • SynonymNA
  • Weight332.743
  • Drugbank_IDDB00628
  • ACS_NO23887-31-2
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.08
  • pkaN/A
  • LogD (pH=7, predicted)-1.89
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.7
  • LogSw (predicted, AB/LogsW2.0)0.17
  • Sw (mg/ml) (predicted, ACD/Labs)0.11
  • No.of HBond Donors4
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds2
  • TPSA102.15
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability91.0
  • Protein binding97.5
  • Volume of distribution (VD)1.24 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThe drug is metabolized in the liver and excreted primarily in the urine. The primary metabolite, nordiazepam, is further metabolized by hydroxylation. The major urinary metabolite is conjugated oxazepam (3-hydroxynordiazepam), and smaller amounts of conjugated p-hydroxynordiazepam and nordiazepam are also found in the urine.
  • Half life93 h
  • ExcretionRenal
  • Urinary Excretion<1
  • Clerance0.17 ml/min/kg
  • ToxicityN/A
  • LD50 (rat) 1320 mg/kg
  • LD50 (mouse)N/A